Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related DSW
Benzinga's Top Upgrades
Morgan Stanley Says Athletic Footwear Is 'The Trend To Play' During Earnings Season
Is Ralph Lauren (RL) Poised for an Earnings Beat in Q1? - Analyst Blog (Zacks)
Related PFE
5 U.S. Mega Caps With Less Than 0.1% Insider Ownership
S&P 500 Index Futures Trading Lower
Regeneron Aims For $1000 As Its Growth Accelerates Yet Again (Seeking Alpha)

Analysts at Sterne Agee downgraded DSW (NYSE: DSW) from Neutral to Underperform. The target price for DSW is set to $23. DSW's shares closed at $27.16 on Friday.

BMO Capital downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform. The target price for Pfizer has been lowered from $34 to $31. Pfizer's shares closed at $30.19 on Friday.

Analysts at Canaccord Genuity downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Buy to Hold. The target price for AcelRx Pharmaceuticals has been lowered from $16.00 to $8.00. AcelRx Pharmaceuticals' shares closed at $10.83 on Friday.

Deutsche Bank downgraded Lear (NYSE: LEA) from Buy to Hold. The target price for Lear has been raised from $100.00 to $103.00. Lear's shares closed at $99.00 on Friday.

Latest Ratings for DSW

DateFirmActionFromTo
Aug 2015KeyBancUpgradesSector WeightOverweight
May 2015Goldman SachsDowngradesBuyNeutral
Mar 2015JefferiesMaintainsBuy

View More Analyst Ratings for DSW
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (DSW + ACRX)

Get Benzinga's Newsletters